Li Yafang, Hu Minli, Chen Yuan, Yang Xiao-Yun, Wang Qunying, Ding Jin, Hu Yibing
Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Med Princ Pract. 2025 Jun 19:1-13. doi: 10.1159/000547015.
Vedolizumab (VDZ) is a key therapeutic option for inflammatory bowel disease (IBD) patients, not responding to conventional treatments. An α4β7 integrin antagonist, VDZ, primarily prevents T-cell migration to the gut by inhibiting the binding of integrins to mucosal vascular address in cellular adhesion molecule. Its gut-selective mechanism of action and safety profile makes it a valuable intervention for treating non-IBD-related diseases, which are difficult to treat and lack standardized guidelines. There is plenty of evidence to suggest that VDZ has therapeutic potential beyond its primary indication in IBD, with clinical applications now extending to immune checkpoint inhibitor-associated colitis, chronic pouchitis, gastrointestinal graft-versus-host disease, and acquired immunodeficiency syndrome. This review aimed to analyze the therapeutic value of VDZ for non-IBD-related diseases and provide a reference for treating these patients. It has been observed that long-term follow-up data are lacking, and additional well-designed large-scale studies are still needed to further validate the efficacy and safety of VDZ.
维多珠单抗（VDZ）是对传统治疗无反应的炎症性肠病（IBD）患者的关键治疗选择。作为一种α4β7整合素拮抗剂，VDZ主要通过抑制整合素与细胞黏附分子中黏膜血管地址素的结合来阻止T细胞迁移至肠道。其肠道选择性作用机制和安全性使其成为治疗难以治疗且缺乏标准化指南的非IBD相关疾病的有价值干预措施。有大量证据表明，VDZ在IBD的主要适应症之外具有治疗潜力，目前其临床应用已扩展至免疫检查点抑制剂相关结肠炎、慢性袋炎、胃肠道移植物抗宿主病和获得性免疫缺陷综合征。本综述旨在分析VDZ对非IBD相关疾病的治疗价值，并为治疗这些患者提供参考。据观察，目前缺乏长期随访数据，仍需要更多精心设计的大规模研究来进一步验证VDZ的疗效和安全性。
